Navigation Links
Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
Date:2/12/2008

CAMBRIDGE, Mass., Feb. 12 /PRNewswire/ -- Mersana, a cancer therapeutics company, announced today that Timothy B. Lowinger, Ph.D., has joined the company as Chief Scientific Officer.

"We are thrilled that Tim is now a part of the Mersana team," said Julie A. Olson, President and CEO at Mersana. "His extensive leadership in oncology research and his experience with polymer-based drug systems are an ideal match for Mersana. In addition to the important impact he will have on our newest programs, his contributions toward advancing our lead product, XMT-1001, and our second product, XMT-1107, will be significant."

Dr. Lowinger has over fifteen years of experience in the pharmaceutical industry and brings a wealth of international experience to his new role in leading our Research team. From 1993 to 2007, Dr. Lowinger held a number of positions at Bayer Pharmaceuticals in the US, Germany, and Japan, where he contributed to the discovery of more than 15 pre-clinical and clinical candidates in a variety of indications. Most notably, he led the team that discovered and advanced Nexavar(R) (sorafenib), an anti-cancer agent that is approved for indications including renal and hepatocellular cancer, with Phase III studies underway in non-small-cell lung and other cancers. Later, as the VP and Department Head of Chemistry Research in West Haven, he managed a department of scientists in the disciplines of medicinal, analytical, computational, combinatorial and synthetic chemistry, focused on the discovery and clinical proof-of-concept of new therapeutics for the treatment of cancer, diabetes and obesity. He has most recently been VP of Chemistry and Pharmaceutical Sciences at Angiotech Pharmaceuticals where he managed a multidisciplinary team of scientists focused on developing polymer-based pharmaceutical products for local administration as well as medical devices incorporating pharmaceutical agents. Dr. Lowinger has a BSc in Chemistry and a Ph.D. in Organic Chemistry from the University of British Columbia in Vancouver, Canada.

About Mersana Therapeutics, Inc.

Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer-camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.


'/>"/>
SOURCE Mersana Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... --  Boston Biomedical , an industry leader in the ... stemness pathways, today announced its Board of Directors has ... Officer, effective April 24, 2017. Ms. ... FACP, who has led Boston Biomedical since he founded ... Biomedical has grown from a "garage startup" without technology ...
(Date:3/22/2017)... ... 2017 , ... Benchworks CEO Thad L. Bench Sr. will participate ... 23-24 in San Diego. The event is a gathering of executive leadership from companies ... President Christian Meyer will also participate in the forum. Participants will discuss the future ...
(Date:3/22/2017)... WI (PRWEB) , ... March 22, 2017 , ... The ... scientific research agencies as outlined in the Administration’s recently published fiscal year 2018 budget ... the National Institutes of Health (NIH) by $5.8 billion or roughly 20% of its ...
(Date:3/22/2017)...   Invitae Corporation (NYSE: NVTA), one ... announced the availability of a new genetic test ... (SMA) , a neuromuscular disease that is one ... as well as a significant cause of progressive ... during the American College of Medical Genetics (ACMG) ...
Breaking Biology Technology:
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- RSA, ... that is designed to enhance fraud detection and ... in the RSA Fraud & Risk Intelligence Suite. ... to leverage additional insights from internal and external ... better protect their customers from targeted cybercrime attacks. ...
(Date:2/10/2017)... -- Research and Markets has announced the ... Scientific and Commercial Aspects" to their offering. ... Biomarkers play ... therapy for selection of treatment as well for monitoring the ... disease in modern medicine. Biochip/microarray technologies and next generation sequencing ...
(Date:2/8/2017)... YORK , Feb. 8, 2017 About ... individual,s voice to match it against a stored ... such as pitch, cadence, and tone are compared ... require minimal hardware installation, as most PCs already ... for different transactions. Voice recognition biometrics are most ...
Breaking Biology News(10 mins):